Alterity Therapeutics Limited, a biotechnology company, has made significant strides in the development of its lead candidate, ATH434, as a potential disease-modifying treatment for Multiple System Atrophy (MSA). During the International Congress of Parkinson’s Disease and Movement Disorders held on October 2, 2024, the company presented multiple data sets from its ongoing clinical trials. The ATH434-202 Phase 2 open-label clinical trial showed promising results, with 30% of participants demonstrating stable or improved clinical outcomes. These 'clinical responders' also exhibited stability in objective biomarkers such as brain iron levels and a protein marker of nerve damage. The company also shared baseline data from the ATH434-201 randomized, double-blind clinical trial, which is evaluating ATH434 in patients with early-stage MSA. The data presented at the congress...Show More

Alterity Therapeutics Limited, a biotechnology company, has made significant strides in the development of its lead candidate, ATH434, as a potential disease-modifying treatment for Multiple System Atrophy (MSA). During the International Congress of Parkinson’s Disease and Movement Disorders held on October 2, 2024, the company presented multiple data sets from its ongoing clinical trials. The ATH434-202 Phase 2 open-label clinical trial showed promising results, with 30% of participants demonstrating stable or improved clinical outcomes. These 'clinical responders' also exhibited stability in objective biomarkers such as brain iron levels and a protein marker of nerve damage. The company also shared baseline data from the ATH434-201 randomized, double-blind clinical trial, which is evaluating ATH434 in patients with early-stage MSA. The data presented at the congress supports the potential of ATH434 to modify disease progression and reduce disability in individuals with MSA. ATH434 has been granted Orphan drug designation by the U.S. FDA and the European Commission for the treatment of MSA. Topline data from the ATH434-201 trial is expected in January 2025, with 12-month data from the ATH434-202 trial anticipated later that year.